References in periodicals archive ?
This new clinical trial will enable us to study whether selective HDAC6 inhibition, which triggers apoptosis in malignant cells, may have a synergistic effect when combined with Revlimid[R] and dexamethasone to treat patients who are relapsed and relapsed/refractory with multiple myeloma.
This patent contains fundamental composition of matter claims covering the Company's selective HDAC6 inhibitor, ACY-1215TM, which is currently being investigated in human clinical trials for the treatment of multiple myeloma.
Wheeler will have responsibility for all clinical development functions of the Company, including current and future clinical trials of Acetylon's HDAC6 selective drug candidate, ACY-1215, in multiple myeloma as well as other potential hematologic and solid tumor disease indications.
BOSTON -- Acetylon Pharmaceuticals today announced the publication of preclinical safety and effectiveness results for its oral selective HDAC6 inhibitor drug candidate, ACY-1215, which has recently entered Phase 1-2a clinical trials in North America.
Selective inhibition of the intracellular enzyme HDAC6 may provide enhanced anti-cancer effectiveness through potentially reduced side effects and improved tolerability compared to current non-selective inhibitors, which are active against both Class I and Class II HDACs.
9 million in funding from The Leukemia & Lymphoma Society announced earlier this quarter in support of clinical development of ACY-1215, the first Class II-selective therapeutic HDAC6 inhibitor candidate.
amp; BOSTON -- The Leukemia & Lymphoma Society (LLS) and Acetylon Pharmaceuticals today announced a newly formed business alliance whereby Acetylon and LLS will jointly support a Phase I/II clinical trial of Acetylon's oral selective HDAC6 inhibitor drug candidate, ACY-1215, in multiple myeloma.
We are particularly excited about the potential we are seeing in preclinical studies for highly selective, potent inhibitors of HDAC6 in treating diseases beyond cancer and about the therapeutic potential for modulation of other members of the Class II HDAC family - areas where Drs.
BOSTON -- Acetylon Pharmaceuticals today announced the publication of favorable results of preclinical safety and efficacy testing of its oral selective HDAC6 inhibitor drug candidate, ACY-1215, in multiple myeloma.
Acetylon plans to use the grant funding to support the initiation of clinical trials of its histone deacetylase-6 (HDAC6) inhibitor lead drug candidate for patients with multiple myeloma and to complete the preclinical development of a second HDAC6 inhibitor for inflammatory autoimmune diseases.
Class IIB enzymes such as HDAC6 have emerged as important targets in inflammatory disease, neurologic disease and broadly in cancer.
The first indications targeted for Acetylon's next-generation HDAC6 inhibitors are multiple myeloma and inflammatory disorders such as rheumatoid arthritis.
Medical browser ?
Full browser ?